The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Pegenzileukin for T-cell dysfunction
T-cell dysfunction from chronic antigen stimulation limits the efficacy of T-cell therapies. Pegenzileukin (formerly known as SAR444245) is a non-alpha IL2, that rescues chronic antigen and CAR-driven T-cell dysfunction in T-cell assays taken from donors. In this video, Michael Green, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses T-cell dysfunction and the potential use of pegenzileukin to mitigate the issues this dysfunction causes. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
